A Blood Test to Predict Alzheimer‘s

One of the greatest challenges to modern medicine is the fight against Alzheimer’s, the most common form of progressive and disabling degenerative dementia. Each year, 7.7 million patients are diagnosed throughout the world.

Given the difficulty of therapeutic intervention in the advanced stages of Alzheimer’s, many efforts have recently been made to understand the onset of the disease. One of the main problems of Alzheimer’s is that serious memory deficits are observed after a long period of “incubation”, in which neurodegenerative processes have already begun. Consequently, late diagnosis occurs and there is less chance for therapy.

Early diagnosis is, thus, fundamental and is exactly what a team of scientists from Washington University School of Medicine in St. Louis has set out to achieve. The team created a new type of test that may be able to detect Alzheimer’s early on and at a reasonable price. Until now, only a special type of positron emission tomography (PET) scan could help detect the risk of onset through the use of a very complex and expensive machine.

If the new test (results published in Neurology) works on a large scale, we would have a new, accurate and easily available instrument to diagnose Alzheimer’s at an incredibly low cost. Anyone, then, could be diagnosed without travelling to specialized structures or undergoing expensive treatments.

How the test works

The test begins by simply taking a blood sample.

Using an instrument called a “mass spectrometer”, the concentration of a certain beta-amyloid in the blood can then be measured. The test focuses on this particular protein because the beta-amyloid has proven to accumulate for years, eventually even forming plaques, in the brains of patients that ultimately manifest Alzheimer’s.

Next, the researchers combined the results with information from other factors, such as the patient’s age and, especially, the presence or lack thereof in the patient’s DNA of the gene “APOE4”, known for multiplying the risk of the disease by five.

The final result is incredibly accurate- 94% accuracy in detecting who will develop Alzheimer’s.

The test must still undergo scientific control processes, but represents an incredible advancement and an unprecedented discovery.

The situation in Italy

There are currently more than 700,000 people in Italy that are affected by a slight cognitive disorder, half of which will progress into a form of dementia (mostly Alzheimer’s) in the next 3 years. These great numbers have also led the research sector in Italy to develop a test – the Interceptor Project.

The project is coordinated by the Foundation of the University of Policlinico A. Gemelli (IRCCS) that leads the participation of a network of 20 Italian neurological structures. This ambitious project is supported and promoted by the Ministry of Health and the Italian Medicines Agency (AIFA), with the collaboration of the Italian National Institute of Health (ISS) and the Italian Association of Alzheimer’s.

The director of Neurology at the University of Policlinico A. Gemelli in Rome, Paolo Maria Rossini, applauded the results of his American colleagues, emphasizing that the results were similar to those achieved in the Italian study last year. According to Rossini, this is an excellent sign that research in this area is gaining momentum, but he also launches an appeal for more investments.

The most important thing about this test is that it is able to achieve an early diagnosis of Alzheimer’s on all fronts so that it becomes routine clinical practice.

© Domedica s.r.l.

Share this article

Share on facebook
Share on twitter
Share on linkedin
Share on email

Related Articles

Our Services

Over 10 years of experience in designing and executing Patient Support Programmes and Support Programmes for Physicians, Clinical Centres and other Constituencies in Health Care.

Our Programmes enhance the quality and effectiveness of care, improve therapy adoption and increase long-term adherence.

We conduct Home Clinical Trials, Observational and Clinical Studies, Behavioural Research, Insights and Impact Analyses, both at an Italian and International level.

Our Projects document, leverage and disseminate high-impact evidence on Therapies and Therapeutic Approaches.

We design and execute multi-channel, e-detailing and online marketing and promotion projects.

We help Clients build and develop long-lasting relationships with key Constituencies, supporting their commercial and promotional strategies.